Cargando…
Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing
The quest for the effective treatment against coronavirus disease 2019 pneumonia caused by the severe acute respiratory syndrome (SARS)‐coronavirus 2(CoV‐2) coronavirus is hampered by the lack of knowledge concerning the basic cell biology of the infection. Given that most viruses use endocytosis to...
Autor principal: | Glebov, Oleg O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276759/ https://www.ncbi.nlm.nih.gov/pubmed/32428379 http://dx.doi.org/10.1111/febs.15369 |
Ejemplares similares
-
In defence of extrapolation but not improvisation in SARS-CoV-2 lung disease
por: Epelbaum, Oleg, et al.
Publicado: (2020) -
SARS-CoV-2 and COVID-19: revisiting the most important research questions
por: Yuen, Kit-San, et al.
Publicado: (2021) -
Considering innate immune responses in SARS-CoV-2 infection and COVID-19
por: Diamond, Michael S., et al.
Publicado: (2022) -
COVID-19 and SARS-CoV-2 Vaccines: A Cameo Role for Headache
por: Martelletti, Paolo
Publicado: (2023) -
Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2022)